Nyrada Inc Announces Cap Raise for TRPC-based Therapies
Key points
- Nyrada Inc is a clinical-stage biotech company developing TRPC-targeted therapies
- Lead drug candidate Xolatryp targets TRPC 3/6/7 channels with broad applicability
- Positive Phase I data supports multiple development pathways across cardioprotection, neuroprotection, and oncology
Full summary
Nyrada Inc, a clinical-stage biotechnology company, is developing a first-in-class small molecule TRPC ion channel inhibitor, Xolatryp, targeting TRPC 3/6/7 channels. The company aims to address calcium dysregulation that drives injury, with potential applications in cardioprotection, oncology, and neuroprotection. Xolatryp is currently in Phase IIa trials for cardiac reperfusion injury. The company has a strong IP position, experienced leadership team, and a commercially focused business model. The cap raise will support ongoing clinical trials and development programs.
Outlook
Nyrada Inc expects to complete Phase IIa trials for cardiac reperfusion injury in Q3/Q4 CY27 and continue advancing programs in oncology, ischemic stroke, and TBI.
Sign in for more about this company, including guidance changes and other insights.
Sign in